BioSight
Companies
Edgewise Therapeutics, Inc. logo

EWTX

NASDAQBOULDER, CO
Edgewise Therapeutics, Inc.

Edgewise Therapeutics is a clinical-stage biotech company developing small molecule therapeutics for muscle diseases using its proprietary drug discovery platform. The company's lead program sevasemten is in clinical development for Duchenne muscular dystrophy, while EDG-7500 and EDG-15400 represent additional clinical-stage candidates, and EDG-003 is a cardiometabolic discovery program in preclinical development.

Price history not yet available for EWTX.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar